<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01711593</url>
  </required_header>
  <id_info>
    <org_study_id>2012P0001076</org_study_id>
    <secondary_id>1U19AI095261</secondary_id>
    <nct_id>NCT01711593</nct_id>
  </id_info>
  <brief_title>Induced Tolerogenic Dendritic Cells as Modulators of Allergic Asthma</brief_title>
  <acronym>MGH-002</acronym>
  <official_title>Induced Tolerogenic Dendritic Cells as Modulators of Allergic Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrew D. Luster, M.D.,Ph.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite advances in medications, allergic diseases, including allergic asthma continue to&#xD;
      rise in prevalence. For this reason, there is a need for a better understanding of the&#xD;
      mechanisms of allergic diseases and novel insights into modulating allergic inflammation. The&#xD;
      investigators hypothesize that much remains to be learned about the behavior of T effector&#xD;
      and T regulatory cells in allergic disease. Furthermore, the investigators hypothesize that&#xD;
      novel mechanisms of allergic tolerance may exist, and elucidation of these mechanisms may&#xD;
      provide insights into novel therapeutic strategies to control allergic diseases. The&#xD;
      investigators will investigate the capacity for T cell tolerance induction in allergic&#xD;
      subjects by a novel type of immune tolerizing dendritic cell (it-DC). The investigators will&#xD;
      assess whether in vitro generated it-DCs have the capacity to induce antigen-specific T&#xD;
      regulatory cells and suppress allergen-specific T effector cell function in vitro.&#xD;
&#xD;
      Standardized Cat Allergen extract and Dust Mite Allergens will be used to generate changes in&#xD;
      the airways that occur during exposure to allergen. For this investigation, the route of&#xD;
      administration will be topical application of the titrated allergen to a bronchoscopically&#xD;
      isolated subsegment of one lobe of one lung. The dose of biologic will be determined from&#xD;
      prior skin-prick testing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, open-label, controlled mechanistic study before-and-after allergen&#xD;
      instillation study that uses each subject as his/her own control. Reliability of study&#xD;
      measurements of expression is accomplished by comparing repeated measurements. Additional&#xD;
      controls are provided by measuring the expression of markers known to have stable expression,&#xD;
      including cell structural proteins and chemokine markers that the investigators know are&#xD;
      induced in this experimental paradigm from our previous studies. This is an investigational&#xD;
      study. Subjects will receive an investigational product, either Standardized Cat Allergen&#xD;
      Extract or Standardized Dust Mite Allergen (Dermatophagoides farinae or D. pteronyssinus). No&#xD;
      subject will be given a placebo. There are 2 cohorts, allergic asthmatics (AA) and healthy&#xD;
      controls (HC). The main comparisons will be measurement of primary and secondary outcome&#xD;
      measures in: (1) diluent versus allergen-challenged segments of the lung in each asthmatic&#xD;
      subject and (2) comparison of these responses in allergic asthmatics (AA) and healthy&#xD;
      controls (HC).&#xD;
&#xD;
      The investigators will enroll 20 AA subjects (10 in Track 1 &amp; 10 in Track 2) and 10 HC&#xD;
      subjects (Track 1). There will be no randomization. The choice of allergen will be determined&#xD;
      by allergy skin testing. When a subject is allergic to both cat and dust mite, one will be&#xD;
      selected with a goal of having a representative sample of cat and dust mite challenges in&#xD;
      each cohort. The 10 allergic asthmatic (AA) subjects and HC subjects in Track 1 will undergo&#xD;
      preliminary screening tests and provide 200 ml of blood for DC and T cell studies on one&#xD;
      occasion. Track 1 subjects will not undergo bronchoscopy, bronchoalveolar lavage, or&#xD;
      segmental allergen challenge. The 10 allergic asthmatic (AA) subjects in Track 2 will undergo&#xD;
      SAC with either standardized cat or mite allergen. These subjects will also donate 200 ml of&#xD;
      blood on two occasions separated by a minimum of 4 weeks and not more than 12 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of it-DC on the phenotype, function, proliferation and survival of allergen-specific effector T cells.</measure>
    <time_frame>24 hours</time_frame>
    <description>We will generate induced tolerogenic dendritic cells (it-DCs) in vitro from peripheral blood monocytes and dendritic cells isolated from each allergic asthmatic subject and assess their capacity to (a) attenuate effector CD4+ T cell (Teff) responses and/or (b) induce T regulatory (Treg) cells from Teff cells as well as CD4+ naïve and memory T cells. Attenuation of T cell responses (a) will be assessed by proliferation assays and cytokine production. Moreover, in order to evaluate the functionality of the it-DC induced Tregs (b), co-culture suppression assays using cat or house dust-mite allergen-specific Teff cells isolated from BAL following segmental allergen challenge (SAC) as responder cells, will be examined. The percent suppression of responding Teff cells will be assessed by examining Teff cell proliferation and survival/apoptosis, and by cytokine production.&#xD;
(Note: SAC samples from healthy controls are not involved in the primary analysis.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent distribution of peripheral blood DC subsets</measure>
    <time_frame>4 weeks</time_frame>
    <description>We will determine the frequency of each peripheral blood DC subset from allergic asthmatic subjects at 0 and 4 weeks using cell surface staining/flow cytometry analysis. Results will be expressed in terms of percent distribution of each DC subset within the total DC pool.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent suppression of naïve T cells (Tn) and memory T cells (Tmem) proliferation by it-DC-induced Tregs from each subject.</measure>
    <time_frame>4 weeks</time_frame>
    <description>The ability of it-DC-induced Tregs from each allergic asthmatic to suppress proliferation of autologous CD4+ Tn and Tmem cells in response to anti-CD3 will be assessed and expressed as a percent suppression of proliferation using an in vitro proliferation assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in proliferation by allergen-specific Teff cells from BAL and blood.</measure>
    <time_frame>4 weeks</time_frame>
    <description>We will measure the proliferative responses in it-DC co-culture assays by allergen-specific CD4+ Teff cells obtained from the BAL of allergic asthmatic subjects as compared to those of blood-derived CD4+ Tmem cells from the same subjects and from 10 healthy controls.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Asthma</condition>
  <condition>Allergies</condition>
  <arm_group>
    <arm_group_label>Allergic Asthmatic, Non-allergic non-asthmatics(HC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Track 1: Adult subjects who are allergic asthmatics or non-allergic non-asthmatics(Healthy Controls) will not receive segmental allergen challenge to the lung but will have their blood drawn at 1 time point. Track 2: Adult subjects who are allergic asthmatics will receive segmental allergen challenge to the lung and have their blood drawn at 2 time points.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bronchoscopy, Segmental Allergen Challenge and Bronchoalveolar Lavage</intervention_name>
    <description>On the first bronchoscopy day,BAL will first be performed in the lingual without instillation of diluent or allergen. A 2ml aliquot of isotonic diluent is instilled into the right upper lobe.The procedure is repeated in the right middle lobe with instillation of 2ml of standardized cat or mite allergen solution. A test dose concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae)or 1/30th(D.pteronyssinus)the threshold concentration.If on visual inspection through the bronchoscope there is no evidence of mucosal inflammation after 2 minutes a second segmental allergen challenge will be done in the right middle lobe using 2ml of full-dose allergen at the threshold concentration(Cat,D.farinae)or 1/3 the threshold concentration(D.pteronyssinus). This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent to obtain BAL fluid from the RUL and RML.</description>
    <arm_group_label>Allergic Asthmatic, Non-allergic non-asthmatics(HC)</arm_group_label>
    <other_name>One of 3 Standardized allergen extracts will be used:</other_name>
    <other_name>1)Cat hair</other_name>
    <other_name>2)Dust Mite Dermatophagoides farinae</other_name>
    <other_name>3)Dust Mite Dermatophagoides pteronyssinus</other_name>
    <other_name>Phenolized saline diluent will also be used in this study.</other_name>
    <other_name>All will be purchased from Greer Laboratories Lenoir,NC.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Phlebotomy</intervention_name>
    <description>200 (40 teaspoons) ml of blood will be obtained from the subjects to collect different leukocyte populations. A second 200 ml of blood will be obtained from the Track 2 subjects 4 weeks later for isolation of T lymphocytes for functional studies.</description>
    <arm_group_label>Allergic Asthmatic, Non-allergic non-asthmatics(HC)</arm_group_label>
    <other_name>Blood Draw</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects with Allergic Asthma (AA subjects):&#xD;
&#xD;
          1. All subjects will have a baseline FEV1 no less than 75 % of the predicted value after&#xD;
             bronchodilator administration.&#xD;
&#xD;
          2. All subjects will have both a clinical history of allergic symptoms to cat or dust&#xD;
             mite allergen and a positive allergen prick test (3 mm diameter greater than diluent&#xD;
             control)&#xD;
&#xD;
          3. Life-long absence of cigarette smoking (lifetime total of &lt; 5 pack-years and none in 5&#xD;
             years).&#xD;
&#xD;
          4. Willing and able to give informed consent.&#xD;
&#xD;
          5. Expressed the desire to participate in an interview with the principal investigator.&#xD;
&#xD;
          6. Age between 18 and 50 years.&#xD;
&#xD;
          7. A methacholine PC20 &lt; 16 mg/ml.&#xD;
&#xD;
          8. Asthma of severity defined as: requiring no more than step 3 therapy (NHLBI&#xD;
             Guidelines, 2007), well-controlled and having a validated asthma control test (ACT)&#xD;
             score of &gt; 19 for one month prior to the screening visit, and able to tolerate a 2&#xD;
             week stoppage of inhaled corticosteroids prior to Visit 2.&#xD;
&#xD;
        Healthy Control Subjects (HC subjects):&#xD;
&#xD;
        Normal control subjects will be individuals who are in good overall health, age and sex&#xD;
        matched to the asthmatic group, age 18 - 50 and nonallergic, i.e. entirely negative on the&#xD;
        panel of prick skin tests with no history of allergic rhinitis or asthma, no history of&#xD;
        allergic symptoms caused by cats or dust mite allergen exposure, life-long nonsmokers of&#xD;
        cigarettes (defined as a lifetime total of less than 5 pack-years and none in 5 years),&#xD;
        normal spirometry (i.e. FEV1 and FVC of at least 90% of predicted) and with a methacholine&#xD;
        PC20 of &gt; 16 mg/ml.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects with Allergic Asthma (AA subjects):&#xD;
&#xD;
          1. Women of childbearing potential who are pregnant (based on urine beta-HCG testing),&#xD;
             are sexually active and not using contraception, are seeking to become pregnant, or&#xD;
             who are nursing.&#xD;
&#xD;
          2. The presence of spontaneous asthmatic episode or clinical evidence of upper&#xD;
             respiratory tract infection within the previous 6 weeks.&#xD;
&#xD;
          3. Participation in a research study involving a drug or biologic during the 30 days&#xD;
             prior to the study.&#xD;
&#xD;
          4. Intolerance to albuterol, atropine, lidocaine, fentanyl, or midazolam.&#xD;
&#xD;
          5. Antihistamines within 7 days of the screening visit.&#xD;
&#xD;
          6. Presence of diabetes mellitus, congestive heart failure, ventricular arrhythmias,&#xD;
             history of a cerebrovascular accident, renal failure, history of anaphylaxis, or&#xD;
             cirrhosis.&#xD;
&#xD;
          7. Use of systemic steroids, increased use of inhaled steroids, beta blockers and MAO&#xD;
             inhibitors or a visit for an asthma exacerbation within 1 month of the screening&#xD;
             visit.&#xD;
&#xD;
          8. Antibiotic use for respiratory disease within 1 month of the characterization visit or&#xD;
             a respiratory tract infection within 6 weeks of the bronchoscopy visits.&#xD;
&#xD;
          9. A history of asthma-related respiratory failure requiring intubation.&#xD;
&#xD;
         10. Quantitative skin-prick test positive reaction down to an allergen concentration of&#xD;
             0.056 BAU or AU/ml.&#xD;
&#xD;
         11. Subjects with a high possibility of poor compliance with the study.&#xD;
&#xD;
         12. Have a history of cigarette smoking within the past 5 years or &gt; 5 pack years total.&#xD;
&#xD;
         13. Having second-hand cigarette smoke exposure or indoor furry pets except in the case of&#xD;
             dog, if the subject is not allergic to the dog and the subject has a negative skin&#xD;
             test to dog.&#xD;
&#xD;
         14. Other lung diseases, such as sarcoidosis, bronchiectasis or active lung infection.&#xD;
&#xD;
         15. Use of Xolair (omalizumab - anti-IgE monoclonal antibody) for 6 months.&#xD;
&#xD;
         16. Immunotherapy with cat or dust mite extract now or in the past.&#xD;
&#xD;
         17. Use of prophylactic aspirin for cardiovascular disease.&#xD;
&#xD;
         18. Non-English speakers.&#xD;
&#xD;
         19. Weight less than 110 pounds&#xD;
&#xD;
         20. Hematocrit &lt; 0.36 for females, &lt;0.38 for males.&#xD;
&#xD;
        Healthy Normal Control Subjects (HC subjects):&#xD;
&#xD;
          1. A history of allergy, asthma, nasal or sinus disease.&#xD;
&#xD;
          2. Exclusion criteria #1, 3-8 and 10-20 from (A.) above.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew D Luster, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>June 28, 2012</study_first_submitted>
  <study_first_submitted_qc>October 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2012</study_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Andrew D. Luster, M.D.,Ph.D.</investigator_full_name>
    <investigator_title>Chief, Division of Rheumatology, Allergy, and Immunology</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Allergic</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Airway</keyword>
  <keyword>Challenge</keyword>
  <keyword>Chemokines</keyword>
  <keyword>Tolerization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dimercaprol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01711593
org study id: 2012P0001076
secondary id: 1U19AI095261
nct id: NCT01711593
lead sponsor: 
collaborator: 
has dmc: Yes
Despite advances in medications, allergic diseases, including allergic asthma continue to
      rise in prevalence. For this reason, there is a need for a better understanding of the
      mechanisms of allergic diseases and novel insights into modulating allergic inflammation. The
      investigators hypothesize that much remains to be learned about the behavior of T effector
      and T regulatory cells in allergic disease. Furthermore, the investigators hypothesize that
      novel mechanisms of allergic tolerance may exist, and elucidation of these mechanisms may
      provide insights into novel therapeutic strategies to control allergic diseases. The
      investigators will investigate the capacity for T cell tolerance induction in allergic
      subjects by a novel type of immune tolerizing dendritic cell (it-DC). The investigators will
      assess whether in vitro generated it-DCs have the capacity to induce antigen-specific T
      regulatory cells and suppress allergen-specific T effector cell function in vitro.

      Standardized Cat Allergen extract and Dust Mite Allergens will be used to generate changes in
      the airways that occur during exposure to allergen. For this investigation, the route of
      administration will be topical application of the titrated allergen to a bronchoscopically
      isolated subsegment of one lobe of one lung. The dose of biologic will be determined from
      prior skin-prick testing.
This is a single-center, open-label, controlled mechanistic study before-and-after allergen
      instillation study that uses each subject as his/her own control. Reliability of study
      measurements of expression is accomplished by comparing repeated measurements. Additional
      controls are provided by measuring the expression of markers known to have stable expression,
      including cell structural proteins and chemokine markers that the investigators know are
      induced in this experimental paradigm from our previous studies. This is an investigational
      study. Subjects will receive an investigational product, either Standardized Cat Allergen
      Extract or Standardized Dust Mite Allergen (Dermatophagoides farinae or D. pteronyssinus). No
      subject will be given a placebo. There are 2 cohorts, allergic asthmatics (AA) and healthy
      controls (HC). The main comparisons will be measurement of primary and secondary outcome
      measures in: (1) diluent versus allergen-challenged segments of the lung in each asthmatic
      subject and (2) comparison of these responses in allergic asthmatics (AA) and healthy
      controls (HC).

      The investigators will enroll 20 AA subjects (10 in Track 1 & 10 in Track 2) and 10 HC
      subjects (Track 1). There will be no randomization. The choice of allergen will be determined
      by allergy skin testing. When a subject is allergic to both cat and dust mite, one will be
      selected with a goal of having a representative sample of cat and dust mite challenges in
      each cohort. The 10 allergic asthmatic (AA) subjects and HC subjects in Track 1 will undergo
      preliminary screening tests and provide 200 ml of blood for DC and T cell studies on one
      occasion. Track 1 subjects will not undergo bronchoscopy, bronchoalveolar lavage, or
      segmental allergen challenge. The 10 allergic asthmatic (AA) subjects in Track 2 will undergo
      SAC with either standardized cat or mite allergen. These subjects will also donate 200 ml of
      blood on two occasions separated by a minimum of 4 weeks and not more than 12 weeks.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Basic Science
masking: None (Open Label)
measure: Effect of it-DC on the phenotype, function, proliferation and survival of allergen-specific effector T cells.
time frame: 24 hours
description: We will generate induced tolerogenic dendritic cells (it-DCs) in vitro from peripheral blood monocytes and dendritic cells isolated from each allergic asthmatic subject and assess their capacity to (a) attenuate effector CD4+ T cell (Teff) responses and/or (b) induce T regulatory (Treg) cells from Teff cells as well as CD4+ naïve and memory T cells. Attenuation of T cell responses (a) will be assessed by proliferation assays and cytokine production. Moreover, in order to evaluate the functionality of the it-DC induced Tregs (b), co-culture suppression assays using cat or house dust-mite allergen-specific Teff cells isolated from BAL following segmental allergen challenge (SAC) as responder cells, will be examined. The percent suppression of responding Teff cells will be assessed by examining Teff cell proliferation and survival/apoptosis, and by cytokine production.
(Note: SAC samples from healthy controls are not involved in the primary analysis.)
measure: Percent distribution of peripheral blood DC subsets
time frame: 4 weeks
description: We will determine the frequency of each peripheral blood DC subset from allergic asthmatic subjects at 0 and 4 weeks using cell surface staining/flow cytometry analysis. Results will be expressed in terms of percent distribution of each DC subset within the total DC pool.
measure: Percent suppression of naïve T cells (Tn) and memory T cells (Tmem) proliferation by it-DC-induced Tregs from each subject.
time frame: 4 weeks
description: The ability of it-DC-induced Tregs from each allergic asthmatic to suppress proliferation of autologous CD4+ Tn and Tmem cells in response to anti-CD3 will be assessed and expressed as a percent suppression of proliferation using an in vitro proliferation assay.
measure: Differences in proliferation by allergen-specific Teff cells from BAL and blood.
time frame: 4 weeks
description: We will measure the proliferative responses in it-DC co-culture assays by allergen-specific CD4+ Teff cells obtained from the BAL of allergic asthmatic subjects as compared to those of blood-derived CD4+ Tmem cells from the same subjects and from 10 healthy controls.
arm group label: Allergic Asthmatic, Non-allergic non-asthmatics(HC)
arm group type: Experimental
description: Track 1: Adult subjects who are allergic asthmatics or non-allergic non-asthmatics(Healthy Controls) will not receive segmental allergen challenge to the lung but will have their blood drawn at 1 time point. Track 2: Adult subjects who are allergic asthmatics will receive segmental allergen challenge to the lung and have their blood drawn at 2 time points.
intervention type: Biological
intervention name: Bronchoscopy, Segmental Allergen Challenge and Bronchoalveolar Lavage
description: On the first bronchoscopy day,BAL will first be performed in the lingual without instillation of diluent or allergen. A 2ml aliquot of isotonic diluent is instilled into the right upper lobe.The procedure is repeated in the right middle lobe with instillation of 2ml of standardized cat or mite allergen solution. A test dose concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae)or 1/30th(D.pteronyssinus)the threshold concentration.If on visual inspection through the bronchoscope there is no evidence of mucosal inflammation after 2 minutes a second segmental allergen challenge will be done in the right middle lobe using 2ml of full-dose allergen at the threshold concentration(Cat,D.farinae)or 1/3 the threshold concentration(D.pteronyssinus). This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent to obtain BAL fluid from the RUL and RML.
arm group label: Allergic Asthmatic, Non-allergic non-asthmatics(HC)
other name: One of 3 Standardized allergen extracts will be used:
other name: 1)Cat hair
other name: 2)Dust Mite Dermatophagoides farinae
other name: 3)Dust Mite Dermatophagoides pteronyssinus
other name: Phenolized saline diluent will also be used in this study.
other name: All will be purchased from Greer Laboratories Lenoir,NC.
intervention type: Procedure
intervention name: Phlebotomy
description: 200 (40 teaspoons) ml of blood will be obtained from the subjects to collect different leukocyte populations. A second 200 ml of blood will be obtained from the Track 2 subjects 4 weeks later for isolation of T lymphocytes for functional studies.
arm group label: Allergic Asthmatic, Non-allergic non-asthmatics(HC)
other name: Blood Draw
criteria: 
gender: All
minimum age: 18 Years
maximum age: 50 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Andrew D Luster, M.D., Ph.D.
role: Principal Investigator
affiliation: Massachusetts General Hospital
facility: 
country: United States
responsible party type: Sponsor-Investigator
investigator affiliation: Massachusetts General Hospital
investigator full name: Andrew D. Luster, M.D.,Ph.D.
investigator title: Chief, Division of Rheumatology, Allergy, and Immunology
mesh term: Asthma
mesh term: Dimercaprol